15 results about "Biflavonoids" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of ginkgetin in preparation of a medicine for delaying senescence of mesenchymal stem cells. The application of the ginkgo biflavone in delaying the aging of the adipose-derived stem cells is explored by exploring the effects of a culture system added with the ginkgo biflavone in delaying the aging process of the adipose-derived stem cells and maintaining the inherent attributes of the adipose-derived stem cells, and a theoretical basis and a technical thought are provided for related intervention of aging and obesity and treatment of related diseases.

The application provides a method for separating biflavonoids from Rhus potaninii flower buds, which specifically comprises the following steps: firstly, taking Rhus potaninii flower bud powder, and refluxing extraction by 95% ethanol, and filtering to obtain a filtrate; then purifying the filtrate by semi-preparative HPLC to obtain an eluate; after detecting the eluate at 300 nm, the eluate with a retention time of 20.5-23.0 min and 38.4-40.6 min is collected; and the eluate is concentrated and evaporated under reduced pressure to obtain biflavonoids Rhusflavanone and Rhusflavone. The separation method is simple, fast, efficient, environmentally friendly, and the obtained biflavonoids have high purity. The obtained biflavonoids can be used as a control sample to determine the content of the biflavonoids in Rhus potaninii and its pseudo-products Rhus succedaneum and Rhus succedaneum, and effectively identify whether the pseudo-products are replaced in the medicinal material or the preparation, and fill the technical blank.

The invention relates to the field of material science and engineering, and particularly discloses a screening method of an anti-macrobrachium rosenbergii iridovirus natural compound based on an MCP protein target. The method comprises the following steps: constructing a three-dimensional structure of a virus major capsid protein MCP and determining an active pocket; performing structure pretreatment on the natural compound library; by taking the active pocket as a target spot, performing multiple rounds of virtual screening through molecular docking to obtain a candidate compound with binding energy less than or equal to-10.0 kcal / mol; and establishing a macrobrachium rosenbergii artificial infection model, determining the virus inhibition rate and protection rate of the candidate compound, and screening the active compound. The eugenol, the amentoflavone, the polyphyllin II and the solamargine screened by the method show a remarkable antiviral effect in an in-vivo injection test and breeding verification. According to the method, accurate screening from target spot prediction to in-vivo verification is realized.

The application discloses active components in Selaginella lepidophylla and application of the active components in inhibition of alpha-glucosidase. The active components comprise four sesquiterpenes, three lignans and three biflavones; wherein, compound 1 is a new sesquiterpene compound, and compounds 2-10 are obtained from Selaginella lepidophylla for the first time. The compounds obtained by separation are subjected to in-vitro enzyme inhibition activity evaluation, so as to lay a scientific foundation for reasonable development and utilization of Selaginella lepidophylla plant resources. The alpha-glucosidase inhibition activity test result shows that compounds 7-10 have good alpha-glucosidase inhibition activity.

The invention relates to the technical field of medicines, in particular to a compound composition for preventing alopecia and promoting hair growth and application thereof. The invention provides a compound composition for preventing hair loss and promoting hair growth. The compound composition is prepared from the following raw materials in parts by weight: 1-5 parts of amentoflavone and 1-10 parts of unodil. The invention provides an application of amentoflavone and unodil in hair loss prevention and hair growth. An in-vitro cell experiment shows that after the amentoflavone and the unodil are combined, the proliferation of human primary dermal papilla cells can be promoted. A preclinical animal experiment shows that after the amentoflavone and the unodil are locally used, the hair growth speed is increased, and the hair density is increased.

The invention relates to the technical field of medicines, and finds that a natural product amentoflavone can be used as a GPR35 (G-protein coupled receptor 35, GPR35) receptor agonist and application thereof, the compound is amentoflavone, has GPR35 receptor agonist activity, is a GPR35 receptor agonist, can be used for treating thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction, and can be used for treating various diseases such as thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction. Therefore, a novel GPR35 receptor stimulant seedling compound with a clear action target can be provided for the related diseases.

This invention discloses a novel biflavonoid compound, its extraction method, and its uses. The extraction method is as follows: extraction with an aqueous ethanol solution, concentration to obtain an extract, followed by extraction with ethyl acetate to obtain an extract. The extract is then subjected to one normal-phase column chromatography separation and one reverse-phase column chromatography separation to obtain a crude product. The crude product is further purified by gel column chromatography to obtain the novel biflavonoid compound. Pharmacological studies have shown that this compound has effective anti-inflammatory properties and is suitable for preparing new drugs for the prevention and treatment of inflammation, possessing broad application prospects and significant potential value.

The invention discloses an extraction method of ginkgo biflavone as well as a product and application thereof, belongs to the technical field of small molecule extraction, and aims to solve the technical problem that the purity and the processability of ginkgo biflavone need to be further improved in the prior art. Phenylboronic acid cured silica gel selective adsorption, L-arginine molecular compounding and double-layer solubilizing auxiliary material construction are used as a core technical path, efficient conversion of the whole process from extraction and purification of ginkgetin to tablet forming is achieved, impurities are removed through specific adsorption, dispersity is improved through molecular compounding, and the bioavailability of ginkgetin is improved. The drug release and the structure stability are jointly regulated and controlled by a quick disintegration solubilizing system and a stable solubilizing system, the obtained tablet is high in purity, quick in disintegration, sufficient in dissolution and excellent in long-term storage performance, and the processability and the bioavailability of the ginkgetin in a solid preparation are comprehensively improved.

This invention relates to natural extracts, specifically to the use of a *Selaginella uncinata* extract in the preparation of medicaments for the treatment and / or prevention of phosphodiesterase type 4 (PDE4)-related diseases. The extract of this invention and the biflavonoids therein possess significant PDE4 inhibitory activity and can be used to prepare PDE4 inhibitors for the treatment and / or prevention of PDE4-related diseases.

The invention belongs to the field of traditional Chinese medicine preparation, and relates to application of biflavone compounds isochamaejasmine and genkwanol A in preparation of anti-complement drugs. According to the present invention, the biflavone compounds such as the isochamaejasme and the genkwanol A are extracted from the ethyl acetate extraction part of the ethanol extract of the dried root of Stellera tianshanica plant Stellera tianshanica Pod. The in-vitro anti-complement activity evaluation experiment results prove that the biflavone compounds such as the isochamaejasme and the genkwanol A have strong inhibition effects on the classical pathway and the alternative pathway of the complement system, wherein the stellera tianshanica and the genkwanol A are extracted from the ethyl acetate extraction part of the ethanol extract of the dried root of Stellera tianshanica Pod. The biflavone compound isochamaejasmine and genkwanol A can be further used for preparing medicines for treating complement related diseases, and the complement related diseases comprise systemic lupus erythematosus, rheumatoid arthritis or acute respiratory distress syndrome.

The application belongs to the field of medicine and chemical industry, and relates to a biflavonoid compound and an extraction method and application thereof. A structural formula of the biflavonoid compound is as shown in formula 1: The biflavonoid compound is prepared through a series of steps such as crushing, extraction, concentration, extraction, column chromatography, HPLC and drying, and has high purity. The anti-HCC activity of the C-O-C bonded biflavonoid compound is better than that of reported C-C bonded amentoflavone and C-O-C bonded taxifolin, and therefore the biflavonoid compound has high potential for preparing hepatocellular carcinoma drugs.

The application discloses a ginkgo biloba biflavonoid extraction method and products and applications thereof, belongs to the technical field of small molecule extraction, and is used for solving the technical problem that the purity and processability of ginkgo biloba biflavonoid need to be further improved in the prior art. The application takes the selective adsorption of phenylboronic acid solidified silica gel, the molecular complexing of L-arginine, and the construction of a double-layer solubilization auxiliary material as core technical paths, realizes efficient conversion of the whole process from ginkgo biloba biflavonoid extraction and purification to tablet forming, removes impurities through specific adsorption, improves dispersibility through molecular complexing, and jointly controls drug release and structure stability through a rapid disintegration solubilization system and a stable solubilization system. The obtained tablet has high purity, fast disintegration, sufficient dissolution, and excellent long-term storage performance, and comprehensively improves the processability and bioavailability of ginkgo biloba biflavonoid in solid preparations.

According to the application of amentotaxus biflavone in preparation of the drug for the sensitivity of the bladder cancer to the cis-platinum, the amentotaxus biflavone synergistically improves the activity and proliferation of the cis-platinum in inhibiting bladder cancer T24 cells and bladder cancer 5637 cells through the specific cytotoxic effect of the amentotaxus biflavone on the T24 cells and the 5637 cells, so that the sensitivity of the bladder cancer to the cis-platinum is enhanced, and the sensitivity of the bladder cancer to the cis-platinum is improved. The compound is used for preparing medicines for treating bladder cancer and belongs to the field of medicines.

The invention provides application of ginkgetin in preparation of a medicine for treating osteoporotic diseases, and belongs to the technical field of medicines, according to the regulation and control effect of ginkgetin on bone loss caused by overactivity of osteoclasts, firstly, it is found that ginkgetin inhibits formation of RANKL-induced osteoclasts through TRAP staining; bone resorption experiments and oxyntobutin discover that the biflavone inhibits the bone resorption and oxyntobutin functions of osteoclasts. Through PCR detection, it is found that ginkgo biflavone inhibits expression of specific genes of osteoclast differentiation. Meanwhile, according to transcriptome sequencing analysis and WB experiment clarification of a basic molecular mechanism, it is found that ginkgo biflavone inhibits generation and differentiation of osteoclasts by regulating and controlling streak OXPHOS. In addition, a femoral artery ligation mouse model is constructed to simulate occurrence of hypoxia osteoporosis, and Hamp is scanned through CT; according to E staining and TRAP staining, the bone destruction degree and the number of osteoclasts are analyzed, and compared with FAL group mice, the ginkgo biflavone treatment group obviously reduces the number of osteoclasts in bone tissues.

The invention discloses an application of amentotaxus biflavone in preparation of a medicine for treating viral sepsis, the amentotaxus biflavone has high affinity to two targets of leukotriene A4 hydrolase (LTA4H) and leukotriene B4 Receptor 1 (Leukotriene B4 Receptor 1, BLT1), can simultaneously inhibit the activity of the LTA4H and the BLT1, and can be used for preparing a medicine for treating the viral sepsis, so that the amentotaxus biflavone can be used for preparing a medicine for treating the viral sepsis. According to the present invention, the virus infection is blocked, the generation of the inflammatory mediator leukotriene B4 mediated by LTA4H is blocked, the inflammatory reaction is amplified by BLT1, the survival rate of the influenza virus infected sepsis mouse model is improved, and the application can be used for preparing the drug for treating viral sepsis.